Company Profile

HaRo Pharmaceutical Inc
Profile last edited on: 11/24/14      CAGE: 64D48      UEI:

Business Identifier: Novel cancer treatments using cell differentiation modulators
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

100 East Lancaster Avenue Suite 231
Wynnewood, PA 19096
   (610) 348-3245
Location: Single
Congr. District: 05
County: Montgomery

Public Profile

HaRo Pharmaceuticals, Inc. is a biotechnology and pharmaceutical company developing hybrid molecules for the treatment of cancer. HaRo's proprietary products, in early stage development, modulate cell differentiation and proliferation in neural crest-derived tumors, leukemia, and other poorly differentiated cancers. HaRo's compounds target just the cancer cells, leaving the surrounding tissue intact and undamaged.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $250,000
Project Title: Optimization of Bifunctional Pharmacophores for the Treatment of Neuroblastoma.

Key People / Management

  David Bettoun

Company News

There are no news available.